Detalhe da pesquisa
1.
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.
J Neurol Neurosurg Psychiatry;
95(2): 134-141, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37558400
2.
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
J Neurol Neurosurg Psychiatry;
95(2): 125-133, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37748927
3.
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry;
95(5): 410-418, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37940409
4.
Rituximab treatment in pediatric-onset multiple sclerosis.
Eur J Neurol;
31(5): e16228, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38375947
5.
IgG and kappa free light chain CSF/serum indices: evaluating intrathecal immunoglobulin production in HIV infection in comparison with multiple sclerosis.
Clin Chem Lab Med;
2024 Apr 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38564810
6.
Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study.
Mult Scler;
29(4-5): 628-636, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36789885
7.
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Eur J Neurol;
30(12): 3789-3798, 2023 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37522464
8.
CYBA allelic variants are associated with severity and recovery in Guillain-Barré syndrome.
J Peripher Nerv Syst;
28(3): 407-414, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37288802
9.
Inflammation-related plasma and CSF biomarkers for multiple sclerosis.
Proc Natl Acad Sci U S A;
117(23): 12952-12960, 2020 06 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32457139
10.
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
Mult Scler;
28(6): 872-884, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34392718
11.
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
Mult Scler;
28(13): 2070-2080, 2022 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35856574
12.
Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world investigation.
J Neurochem;
159(3): 618-628, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34478561
13.
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Ann Neurol;
87(5): 688-699, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32056253
14.
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study.
J Neurol Neurosurg Psychiatry;
92(2): 189-194, 2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33106366
15.
Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular Identifiers.
Clin Chem;
66(9): 1228-1237, 2020 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32814950
16.
Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.
Mult Scler;
26(12): 1532-1539, 2020 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31392923
17.
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Mult Scler;
26(13): 1719-1728, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31675266
18.
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Mult Scler;
26(14): 1866-1876, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31762387
19.
Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection.
J Neuroinflammation;
16(1): 16, 2019 Jan 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30678707
20.
An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: a prospective observational study.
J Antimicrob Chemother;
74(12): 3565-3572, 2019 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31504577